このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

中程度から重度の湿疹を伴う2歳以上の子供のアブリシチニブと呼ばれる薬の長期的な研究

2026年11月3日 更新者:Pfizer

アブリシチニブの安全性と有効性を評価するフェーズ3、マルチセンター、長期、オープンラベル研究、2歳以上の小児皮膚炎の小児の参加者に投与された局所投与の有無にかかわらず、

This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis. The study will enroll two groups: participants who have completed other abrocitinib studies and participants who have never participated in abrocitinib studies.

調査の概要

状態

募集

介入・治療

詳細な説明

Phase 3, open-label study to assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children ≥2 years of age with moderate-to-severe atopic dermatitis (AD). This study will enroll participants in two cohorts: an extension cohort of participants who previously completed prior abrocitinib studies, and a de novo cohort of participants (6 to <12 years of age) who have not participated in previous abrocitinib studies. Study duration will be up to 2 years (or commercial availability, whichever occurs earlier). The study will enroll a maximum of approximately 500 participants with moderate-to-severe Atopic Dermatitis from study sites globally (extension cohort will enroll up to 320 participants; de novo cohort will enroll approximately 180 participants). All participants will receive the study intervention abrocitinib oral suspension.

研究の種類

介入

入学 (推定)

450

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Alabama
      • Birmingham、Alabama、アメリカ、35244
        • 募集
        • Cahaba Dermatology & Skin Health Center
    • Arkansas
      • North Little Rock、Arkansas、アメリカ、72117
        • 募集
        • Arkansas Research Trials
    • California
      • San Diego、California、アメリカ、92123
        • 募集
        • Investigational Drug Service - Rady Childrens Hospital-San Diego
      • San Diego、California、アメリカ、92123
        • 募集
        • University of California, San Diego/ Rady Children's Hospital - San Diego
    • Florida
      • Jacksonville、Florida、アメリカ、32256
        • 募集
        • Solutions Through Advanced Research
    • Idaho
      • Meridian、Idaho、アメリカ、83646
        • 募集
        • Ada West Research - Meridian
    • Indiana
      • Indianapolis、Indiana、アメリカ、46250
        • 募集
        • Dawes Fretzin Clinical Research Group, LLC
    • Missouri
      • St Louis、Missouri、アメリカ、63104
        • 募集
        • Saint Louis University
    • South Carolina
      • Charleston、South Carolina、アメリカ、29425
        • 募集
        • Medical University of South Carolina - South Carolina Translational Research Nexus Clinic
      • Greenville、South Carolina、アメリカ、29607
        • 募集
        • Tribe Clinical Research, LLC
    • Texas
      • San Antonio、Texas、アメリカ、78235
        • 募集
        • Texas Dermatology and Laser Specialists
      • Zaragoza、スペイン、50009
        • 募集
        • Hospital Universitario Miguel Servet
    • A Coruña [LA Coruña]
      • Santiago de Compostela、A Coruña [LA Coruña]、スペイン、15706
        • 募集
        • CHUS - Hospital Clinico Universitario
    • Barcelona
      • Granollers、Barcelona、スペイン、08402
        • 募集
        • Hospital General de Granollers
    • Baranya
      • Pécs、Baranya、ハンガリー、7632
        • 募集
        • Pécsi Tudományegyetem Klinikai Központ
    • Bekes County
      • Békéscsaba、Bekes County、ハンガリー、5600
        • 募集
        • Trial Pharma Kft.
    • Csongrád-csanád
      • Szeged、Csongrád-csanád、ハンガリー、6720
        • まだ募集していません
        • University of Szeged
    • Pest County
      • Budapest、Pest County、ハンガリー、1033
        • 募集
        • Clinexpert Kft.
    • Lesser Poland Voivodeship
      • Krakow、Lesser Poland Voivodeship、ポーランド、30-002
        • 募集
        • Specjalistyczny Gabinet Dermatologiczny Aplikacyjno-Badawczy, Marek Brzewski, Paweł Brzewski spółka cywilna
    • Lublin Voivodeship
      • Lublin、Lublin Voivodeship、ポーランド、20-573
        • 募集
        • LUXDERM Specjalistyczny Gabinet Dermatologiczny prof. dr hab. n. med. Dorota Krasowska
    • Masovian Voivodeship
      • Warsaw、Masovian Voivodeship、ポーランド、02-625
        • 募集
        • Centrum Medyczne Evimed
    • Silesian Voivodeship
      • Chorzów、Silesian Voivodeship、ポーランド、41-500
        • 募集
        • DERMAPOLIS Medical Dermatology Center dr n. med. Edyta Gebska
    • Łódź Voivodeship
      • Lodz、Łódź Voivodeship、ポーランド、90-436
        • 募集
        • Dermoklinika - Centrum Medyczne spółka cywilna M. Kierstan, J. Narbutt, A. Lesiak
    • Świętokrzyskie Voivodeship
      • Ostrowiec Świętokrzyski、Świętokrzyskie Voivodeship、ポーランド、27-400
        • 募集
        • Dermedic Jacek Zdybski
      • Chihuahua City、メキシコ、31238
        • まだ募集していません
        • Servicios Hospitalarios de Mexico S.A. DE C.V.
    • Mexico City
      • Mexico City、Mexico City、メキシコ、06720
        • まだ募集していません
        • Hospital Infantil de Mexico Federico Gomez
    • Nuevo León
      • Monterrey、Nuevo León、メキシコ、64718
        • まだ募集していません
        • Eukarya Pharmasite S.C.
    • Veracruz Ignacio de LA Llave
      • Veracruz、Veracruz Ignacio de LA Llave、メキシコ、91900
        • まだ募集していません
        • Arké SMO S.A de C.V
      • Shanghai、中国、200062
        • 募集
        • Shanghai Children's Hospital
      • Shanghai、中国、200092
        • 募集
        • Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine
    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100045
        • 募集
        • Beijing Children's hospital, Capital Medical University
    • Guangdong
      • Shenzhen、Guangdong、中国、518026
        • 募集
        • Shenzhen Children's Hospital
    • Hunan
      • Changsha、Hunan、中国、410007
        • 募集
        • Hunan Children's Hospital
    • Jiangxi
      • Nanchang、Jiangxi、中国、330000
        • まだ募集していません
        • Dermatology Hospital of Jiangxi Province
    • Zhejiang
      • Hangzhou、Zhejiang、中国、310009
        • 募集
        • Hangzhou Third People's Hospital
      • Fukuoka、日本、811-1394
        • 募集
        • Fukuoka National Hospital
      • Fukuoka、日本、819-0042
        • 募集
        • Saruta Dermatology Clinic
    • Kanagawa
      • Yokohama、Kanagawa、日本、220-6208
        • 募集
        • Queen's square Medical Facilities Queen's square Dermatology and Allergology
    • Osaka
      • Sakai、Osaka、日本、593-8324
        • 募集
        • Dermatology and Ophthalmology Kume Clinic
    • Tokyo
      • Setagaya-ku、Tokyo、日本、157-0066
        • 募集
        • Sasamoto Children's Clinic

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

2年~11年 (子)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria for the Extension Cohort:

1. Participants who have completed the treatment phase of the qualifying parent study (age 2 to <12 years old).

• No contraception methods are required for male participants. Female participants must not be pregnant or breastfeeding and, if the participant is of child-bearing potential, must use a highly effective form of contraception (i.e., abstinence) during the study intervention period and for at least 28 days after the last dose of study intervention.

Inclusion Criteria for the De Novo Cohort:

Age

  1. Children aged 6 to <12 years at the time of informed consent/assent.

    • No contraception methods are required for male participants.

    Disease Characteristics:

  2. Participants who meet all of the following AD criteria:

    • A documented diagnosis of chronic AD for at least 6 months prior to screening and confirmed at screening and baseline visits according to the Hanifin and Rajka criteria; and
    • A diagnosis of moderate-to-severe AD at the baseline visit (must fulfill all of the following criteria: BSA ≥10%, vIGA ≥3, EASI ≥16, and WI-NRS ≥4); and
    • Documented history (within 6 months of the screening visit) of inadequate response to treatment with topical medical therapy for AD (eg, TCS and TCI), for at least 4 weeks and are candidates for systemic therapy.

    Other Inclusion Criteria:

  3. Body weight ≥15 kg

Exclusion Criteria for the Extension Cohort:

Medical Conditions:

  1. Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

    If the participant has SDQ total score ≥17, the investigator should exclude the child or refer them to a pediatric MHP to determine if it is safe to participate in the study. A copy or summary of the evaluation should be placed in the site source documents.

    Prior/Concomitant Therapy:

  2. Required use of any prohibited concomitant treatments outlined in Section 6.9.3 and Appendix 9 of study protocol.

  3. Required vaccination with live attenuated vaccines during study treatment and for 6 weeks after discontinuing study treatment.

    Diagnostic Assessments:

  4. Ongoing adverse event in the parent studies which in the opinion of the investigator, or sponsor, is an ongoing safety concern OR the participant is currently triggering safety monitoring criteria.

  5. Discontinued from treatment early in the parent studies OR triggered a discontinuation criterion at any point during the parent studies OR meets exclusion criteria from the parent studies which in the opinion of the investigator, or sponsor, is an ongoing safety concern.

Exclusion Criteria for the De Novo Cohort

Medical Conditions:

  1. Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

    If the participant has SDQ total score ≥17, the investigator should exclude them or refer the child to a pediatric MHP to determine if it is safe to participate in the study. A copy or summary of the evaluation should be placed in the site source documents.

  2. Have any of the following medical conditions:

    • Infections:

      • Skin infections that require treatment with systemic antimicrobials within 2 weeks prior to Day 1 (baseline) or have superficial skin infections within 1 week of Day 1.
      • History of systemic infection requiring hospitalization or parenteral antimicrobial therapy or as otherwise judged clinically significant by the investigator within 1 month prior to Day 1.
      • Have a history (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent localized, dermatomal herpes zoster.
      • Infection with HIV, hepatitis B, and/or hepatitis C
      • Evidence of active TB or inadequately treated latent TB.
    • Skin Conditions:

      - Including but not limited to psoriasis, seborrheic dermatitis or lupus on Day 1 that would interfere with evaluation of AD or response to treatment.

    • Other Conditions:

      • Documented history of skeletal dysplasia.
      • Documented history of retinal detachment.
      • History of or conditions associated with thrombocytopenia, coagulopathy or platelet dysfunction.
      • Prior history of leukemia, lymphoma, sarcoma or any other malignancy.
      • Immunodeficiency disorder or a first-degree relative with a hereditary immunodeficiency.
      • Any other medical conditions that in the investigator's judgment make the participant inappropriate for the study.

    Prior/Concomitant Therapy:

  3. Prior treatment with a systemic JAK inhibitor for AD.

  4. Live attenuated vaccination within 6 weeks prior to Day 1 or require vaccination with live attenuated vaccines during treatment or within 6 weeks after the last dose of study intervention.

  5. Concomitant use of strong inhibitors and inducers of CYP2C19 enzymes and strong inducers of CYP2C9 enzymes is not allowed in the study.

    Prior/Concurrent Clinical Study Experience:

  6. Previous administration of an investigational drug within 30 days or 5 half lives, whichever is longer, of Day 1.

    Diagnostic Assessments:

  7. Hepatic and/or renal and/or hematological abnormalities defined as:

    • AST >2 x ULN
    • Hemoglobin <10 g/dL
    • ALT >2 x ULN
    • ANC <1000/mm3
    • Total bilirubin ≥1.5 x ULN
    • ALC <500/mm3
    • eGFR <60 mL/min/1.73 m2
    • Platelets <150,000 /mm3

    Other Exclusion Criteria:

  8. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Extension

Patients who have completed other abrocitinib studies

Abrocitinib administered as liquid oral suspension.

他の名前:
  • PF-04965842
実験的:De novo

Patients who have not participated other abrocitinib studies

Abrocitinib administered as liquid oral suspension.

他の名前:
  • PF-04965842

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and adverse events (AEs) that lead to study discontinuation
時間枠:0-24 months

The number of the treatment emergent adverse events, serious adverse events and adverse events leading to discontinuation among patients with moderate-to-severe disease treated with abrocitinib regardless of discontinuation from study treatment.

0-24 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Number of Participants With Clinically Significant Laboratory Abnormalities
時間枠:0-24 months

The number of clinically significant laboratory abnormalities among participants with moderate-to-severe disease treated with abrocitinib.

0-24 months
Response based on achieving Validated Investigator's Global Assessment (vIGA) score of clear (0) or almost clear (1) (on a 5-point scale) and a 2 -point reduction from baseline at all scheduled time points
時間枠:Baseline, 24 months

Proportion of responders based on vIGA at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib

Baseline, 24 months
Percentage of Response based on achieving a ≥4 point improvement from baseline in the Worst Itch Numerical Rating Scale (WI-NRS) at all scheduled time points in participants aged ≥2 to <6 years
時間枠:0-24 months

Percentage of responders based on achieving an improvement ≥4 points from baseline at all scheduled time points in the WI-NRS (in patients aged ≥2 to <6 years) with moderate-to-severe disease treated with abrocitinib.

0-24 months
Percentage of Response based on achieving a ≥4-point improvement from baseline in the WSI-NRS at all scheduled time points in participants aged ≥6 to 12 years
時間枠:0-24 months

Percentage of responders based on achieving an improvement ≥4 points from baseline at all scheduled time points in the WSI-NRS (in patients aged ≥6 to 12 years) with moderate-to-severe disease treated with abrocitinib.

0-24 months
Percentage of Responders based on achieving Eczema Area and Severity Index (EASI)-50, EASI-90 and EASI-100 at all scheduled time points in participants with moderate-to-severe disease treated with abrocitinib
時間枠:0-24 months

Percentage of response based on achieving ≥50%, ≥90%, 100% improvement from parent study baseline in the EASI total score (EASI-50, EASI-90, EASI-100) at all scheduled time points.

0-24 months
Percent Change from Baseline (CFB) in EASI total score at all scheduled time points.
時間枠:0-24 months

Mean percent CFB in EASI total score at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib

0-24 months
Percentage of Participants with Flares
時間枠:0-24 months

Percentage of participants reporting flares in patients with moderate-to-severe disease treated with abrocitinib.

0-24 months
CFB in the percentage Body Surface Area (BSA) affected at all scheduled time points
時間枠:0-24 months

Mean CFB in BSA affected at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib.

0-24 months
CFB in Children's Dermatology Life Quality Index (CDLQI) at all scheduled time points.
時間枠:0-24 months

Mean CFB in CDLQI at all scheduled time points in participants aged ≥4 to <16 years with moderate-to-severe disease treated with abrocitinib.

0-24 months
CFB in in Infants' Dermatitis Quality of Life (IDQOL) Index at all scheduled time points
時間枠:0-24 months

Mean CFB in IDQOL Index or CDQLI depending on age at all scheduled time points in participants aged <4 years with moderate-to-severe disease treated with abrocitinib

0-24 months
CFB in Patient-Oriented Eczema Measure (POEM) at all scheduled time points
時間枠:0-24 months

Mean CFB in POEM at all scheduled time points in participants with moderate-to-severe disease treated with abrocitinib.

0-24 months
CFB in Dermatitis Family Impact (DFI) at all scheduled time points
時間枠:0-24 months

Mean CFB in DFI at all scheduled time points in participants with moderate-to-severe disease treated with abrocitinib.

0-24 months
CFB in Patient Global Impression of Severity (PGIS) at all scheduled time points
時間枠:0-24 months

Mean CFB in PGIS (in patients aged 6 to <12 years) at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib.

0-24 months
CFB in Observer Reported Global Impression of Severity (OGIS) at all scheduled time points
時間枠:0-24 months

Mean CFB in OGIS (in patients aged 2 to <6 years) at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib

0-24 months
CFB in the the EuroQol- 5 Dimension Youth (EQ-5D-Y)
時間枠:0-24 months

Mean CFB in EQ-5D-Y at all scheduled time points in patients with moderate-tosevere AD treated with abrocitinib versus placebo.

0-24 months
Number of topical corticosteroid and /or topical calcineurin inhibitor free days
時間枠:0-24 months

Mean number of days free from topical corticosteroids and /or topical calcineurin inhibitor use in patients with moderate-to-severe disease treated with abrocitinib.

0-24 months
Percentage of Participants Achieving satisfactory response in Tdap/DTaP and/or pneumococcal antibody titers as appropriate in participants who receive Tdap/DTaP and/or pneumococcal vaccinations
時間枠:0-24 months

For patients that receive Tdap/ DTap and/or pneumococcal vaccinations during the study, the proportion of patients treated with abrocitinib who achieve satisfactory immunogenicity at 4 weeks after receiving the vaccinations.

0-24 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Pfizer CT.gov Call Center、Pfizer

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年12月2日

一次修了 (推定)

2032年2月22日

研究の完了 (推定)

2032年2月22日

試験登録日

最初に提出

2025年1月29日

QC基準を満たした最初の提出物

2025年1月29日

最初の投稿 (実際)

2025年2月4日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月5日

QC基準を満たした最後の更新が送信されました

2026年11月3日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する